What is the efficacy of high-dose daunorubicin for the treatment of acute myeloid leukemia (AML) in elderly patients?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

A study in elderly patients with newly diagnosed AML compared conventional-dose daunorubicin (45 mg/m2/d for 3 d) with high-dose daunorubicin (90 mg/m2/d for 3 d). [43] These regimens were administered with cytarabine 200 mg/m2/d for 7 days for the first cycle. A second cycle of cytarabine alone (1000 mg/m2/d for 6 d) was also administered. Complete remission occurred in 64% in the high-dose daunorubicin group compared with 54% in the conventional-dose group [43] ; remission after the first cycle was 52% in the high-dose daunorubicin group compared with 35% in the conventional-dose group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!